L.-T. Chen

发表

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma

J. Whang‐Peng, W. Su, J. Chang, 2013, Alimentary pharmacology & therapeutics.

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

I. Sheen, Y. Chao, J. Wang-Peng, 2010, British Journal of Cancer.

JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.

Y. Kodera, E. Baba, J. Tabernero, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

α‐fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

S. Juang, Y. Chin, S. Chen, 2005 .

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

M. Tempero, W. Su, Li‐Tzong Chen, 2013, British Journal of Cancer.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

J. Gribben, J. Fitzgibbon, L. Maharaj, 2012, Cell Death and Disease.

Differential response to H. pylori eradication therapy of co‐existing diffuse large B‐cell lymphoma and MALT lymphoma of stomach—significance of tumour cell clonality and BCL10 expression

K. Yeh, H. Hsu, P. Yeh, 2007, The Journal of pathology.

O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

David Cunningham, G. Bodoky, D. Cunningham, 2014 .

Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis.

J. Chang, C.-C. Chen, K.-J. Liu, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Limitations of Wright formula estimates of renal function

J. Chang, C.-C. Chen, K.-J. Liu, 2005 .

Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma

Chung-Wu Lin, A. Cheng, S. Kuo, 2014, Blood Cancer Journal.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

F. Izzo, M. Colombo, Sheng-Nan Lu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer

J. Chang, P. Chu, Y-C Lee, 2011, Oncogene.

Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity

K. Yeh, A. Cheng, S. Kuo, 2014, Blood Cancer Journal.

Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.

J. Whang‐Peng, J. Chang, J-Y Chang, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

Y. Chao, C. Yen, P. Lin, 2010, British Journal of Cancer.

Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study.

T. Hwang, Y. Chiu, Yu-Wen Tien, 2018, Annals of Oncology.

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

S. Oh, S. Sym, I. Chung, 2020 .

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan

D. Hwang, Y. Shan, N. Chiang, 2022, ESMO open.

Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1.

T. Bekaii-Saab, B. Mirakhur, J. Blanc, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary embolism after transcatheter arterial chemoembolization.

J. Whang‐Peng, J. Chang, J. M. Liu, 2005, European journal of cancer care.

Cervical carcinoma progression is aggravated by lncRNA ZNF281 by binding KLF15.

X-x Zheng, X. Wang, Chenyi Shen, 2021, European Review for Medical and Pharmacological Sciences.

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).

M. Azuma, M. Ryu, W. Kang, 2019 .

Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance

K. Yeh, A. Cheng, S. Kuo, 2013, Blood Cancer Journal.

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

J. Chang, T. Tsou, C. Kuo, 2007, British Journal of Cancer.

P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma

Yen-Wen Wu, C. Hsiao, T. Chou, 2021, Annals of Oncology.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial.

M. Osada, M. Ikeda, D. Oh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.

K. Muro, T. Tamura, W. Kang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

H. Burris, A. Avallone, S. Qin, 2022, Annals of Oncology.

Kyung Won Lee, K. Lee, Yoon-Koo Kang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

G. Bodoky, D. Cunningham, E. Bayever, 2016 .

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

K. Rau, Chih-Hung Hsu, Chung-Pin Li, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.